$ATAI
ATAI Life Sciences N.V. Stock $atai

$atai Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024038138 Filed on March 28, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023 Q3
Revenue	$0.00	$18.00K	$87.00K
YoY Change	-100.0%	-52.63%	262.5%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$12.56M	$19.42M	$13.63M
YoY Change	-10.13%	23.5%	-29.81%
% of Gross Profit
Research & Development	$11.53M	$14.16M	$13.29M
YoY Change	-40.2%	-35.29%	-30.16%
% of Gross Profit
Depreciation & Amortization	$83.00K	$99.00K	$80.00K
YoY Change	27.69%	86.79%	122.22%
% of Gross Profit
Operating Expenses	$24.09M	$33.58M	$26.92M
YoY Change	-27.57%	-10.7%	-29.98%
Operating Profit	-$24.09M		-$26.83M
YoY Change	-27.49%		-30.16%
Interest Expense	$687.0K	-$69.35M	$686.0K
YoY Change	10.45%	1466.88%	-85.14%
% of Operating Profit
Other Income/Expense, Net	-$1.596M	$85.54M	$70.68M
YoY Change	-2851.72%	3103.82%	1236.38%
Pretax Income	-$25.68M	-$18.32M	$43.85M
YoY Change	-22.54%	-53.41%	-232.33%
Income Tax	-$4.000K	$428.0K	$200.0K
% Of Pretax Income			0.46%
Net Earnings	-$26.71M	-$18.29M	$44.24M
YoY Change	-19.38%	-59.36%	-230.56%
Net Earnings / Revenue		-101622.22%	50855.17%
Basic Earnings Per Share	-$0.17		$0.28
Diluted Earnings Per Share	-$0.17	-$0.11	$0.25
COMMON SHARES
Basic Shares Outstanding	166.0M	166.0M	166.0M
Diluted Shares Outstanding	158.9M		177.6M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$106.2M	$179.3M	$209.0M
YoY Change	-57.48%	-34.36%	-31.26%
Cash & Equivalents	$18.90M	$45.00M	$76.50M
Short-Term Investments	$87.38M	$134.2M	$132.5M
Other Short-Term Assets	$1.280M	$846.0K	$638.0K
YoY Change	-35.42%	-51.52%	-53.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$117.5M	$185.6M	$215.8M
YoY Change	-56.15%	-35.37%	-32.02%
LONG-TERM ASSETS
Property, Plant & Equipment	$920.0K	$981.0K	$992.0K
YoY Change	-17.41%	5.71%	36.26%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$123.0M	$0.00	$0.00
YoY Change	2004.21%
Other Assets	$2.574M	$2.720M	$3.107M
YoY Change	-19.06%	-18.83%	-64.44%
Total Long-Term Assets	$151.6M	$107.9M	$92.40M
YoY Change	1086.02%	489.67%	267.89%
TOTAL ASSETS
Total Short-Term Assets	$117.5M	$185.6M	$215.8M
Total Long-Term Assets	$151.6M	$107.9M	$92.40M
Total Assets	$269.1M	$293.5M	$308.2M
YoY Change	-4.13%	-3.92%	-10.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.843M	$4.589M	$5.506M
YoY Change	-21.81%	91.29%	56.82%
Accrued Expenses	$10.93M	$15.26M	$13.01M
YoY Change	-20.93%	-11.85%	-41.25%
Deferred Revenue
YoY Change
Short-Term Debt	$87.40M	$109.2M	$132.5M
YoY Change	36.56%	32.36%	-17.96%
Long-Term Debt Due	$0.00	$0.00	$0.00
YoY Change
Total Short-Term Liabilities	$15.01M	$20.12M	$19.70M
YoY Change	-24.76%	1.12%	-24.0%
LONG-TERM LIABILITIES
Long-Term Debt	$19.66M	$17.88M	$15.40M
YoY Change	29.27%	18.26%	2.66%
Other Long-Term Liabilities	$8.275M	$7.918M	$2.736M
YoY Change	193.86%	113.54%	-25.95%
Total Long-Term Liabilities	$8.275M	$7.918M	$2.736M
YoY Change	193.86%	113.54%	-25.95%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.01M	$20.12M	$19.70M
Total Long-Term Liabilities	$8.275M	$7.918M	$2.736M
Total Liabilities	$45.86M	$49.16M	$39.71M
YoY Change	14.44%	23.91%	-14.64%
SHAREHOLDERS EQUITY
Retained Earnings	-$577.7M	-$550.9M	-$532.6M
YoY Change	6.23%	7.98%	14.49%
Common Stock	$18.60M	$18.57M	$18.57M
YoY Change	0.16%	0.06%	0.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$222.5M	$243.0M	$266.3M
YoY Change
Total Liabilities & Shareholders Equity	$269.1M	$293.5M	$308.2M
YoY Change	-4.13%	-3.92%	-10.03%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023 Q3
OPERATING ACTIVITIES
Net Income	-$26.71M	-$18.29M	$44.24M
YoY Change	-19.38%	-59.36%	-230.56%
Depreciation, Depletion And Amortization	$83.00K	$99.00K	$80.00K
YoY Change	27.69%	86.79%	122.22%
Cash From Operating Activities	-$22.57M	-$21.96M	-$18.43M
YoY Change	6.93%	-28.02%	-34.28%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$20.00K	$0.00
YoY Change	-100.0%	-91.03%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$11.48M	-$805.0K	-$46.48M
YoY Change	-30.28%	-101.0%	-169.81%
Cash From Investing Activities	$11.47M	-$825.0K	-$46.48M
YoY Change	-28.39%	-101.03%	-170.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	-8.465M	0.000
YoY Change	-100.0%	818.11%	-100.0%
NET CHANGE
Cash From Operating Activities	-22.57M	-21.96M	-18.43M
Cash From Investing Activities	11.47M	-825.0K	-46.48M
Cash From Financing Activities	0.000	-8.465M	0.000
Net Change In Cash	-11.17M	-31.25M	-64.91M
YoY Change	136.17%	-164.26%	-212.33%
FREE CASH FLOW
Cash From Operating Activities	-$22.57M	-$21.96M	-$18.43M
Capital Expenditures	$0.00	$20.00K	$0.00
Free Cash Flow	-$22.57M	-$21.98M	-$18.43M
YoY Change	5.53%	-28.48%	-33.02%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	00000
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001840904
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Property Plant And Equipment Useful Life Description Of Term Extensible Enumeration PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration	http://fasb.org/us-gaap/2023#LeaseholdImprovementsMember
CY2022Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OperatingLeaseRightOfUseAsset
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OperatingLeaseRightOfUseAsset
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OperatingLeaseRightOfUseAsset
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityNoncurrent
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityNoncurrent
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40493
CY2023	dei	Entity Registrant Name EntityRegistrantName	ATAI Life Sciences N.V.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	P7
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	ATAI Life Sciences N.V.
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Wallstraße 16, 10179
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Berlin
CY2023	dei	Entity Address Country EntityAddressCountry	DE
CY2023	dei	City Area Code CityAreaCode	49 89
CY2023	dei	Local Phone Number LocalPhoneNumber	2153 9035
CY2023	dei	Security12b Title Security12bTitle	Common shares, par value €0.10 per share
CY2023	dei	Trading Symbol TradingSymbol	ATAI
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	203300000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	166026396
CY2023	dei	Auditor Firm AuditorFirmId	34
CY2023	dei	Auditor Name AuditorName	DELOITTE & TOUCHE LLP
CY2023	dei	Auditor Location AuditorLocation	New Jersey
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	45034000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	190613000
CY2023Q4	atai	Debt Securities Carried At Fair Value DebtSecuritiesCarriedAtFairValue	109223000
CY2022Q4	atai	Debt Securities Carried At Fair Value DebtSecuritiesCarriedAtFairValue	82496000
CY2023Q4	atai	Committed Investment Funds CommittedInvestmentFunds	25000000
CY2022Q4	atai	Committed Investment Funds CommittedInvestmentFunds	0
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5830000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14036000
CY2023Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	505000
CY2022Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	0
CY2023Q4	us-gaap	Assets Current AssetsCurrent	185592000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	287145000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	981000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	928000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1223000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	226000
CY2023Q4	us-gaap	Restricted Investments At Fair Value RestrictedInvestmentsAtFairValue	89825000
CY2022Q4	us-gaap	Restricted Investments At Fair Value RestrictedInvestmentsAtFairValue	0
CY2023Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	1838000
CY2022Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	6755000
CY2023Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	97000
CY2022Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	7262000
CY2023Q4	us-gaap	Notes Receivable By Owner To Limited Liability Company Llc NotesReceivableByOwnerToLimitedLiabilityCompanyLLC	11202000
CY2022Q4	us-gaap	Notes Receivable By Owner To Limited Liability Company Llc NotesReceivableByOwnerToLimitedLiabilityCompanyLLC	0
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2720000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3125000
CY2023Q4	us-gaap	Assets Assets	293478000
CY2022Q4	us-gaap	Assets Assets	305441000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4589000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2399000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15256000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17306000
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	275000
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	180000
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	0
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	12000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20120000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19897000
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	620000
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	953000
CY2023Q4	atai	Contingent Consideration Liability ContingentConsiderationLiability	1637000
CY2022Q4	atai	Contingent Consideration Liability ContingentConsiderationLiability	0
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	990000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44000
CY2023Q4	atai	Convertible Promissory Notes Related Parties Transaction ConvertiblePromissoryNotesRelatedPartiesTransaction	164000
CY2022Q4	atai	Convertible Promissory Notes Related Parties Transaction ConvertiblePromissoryNotesRelatedPartiesTransaction	415000
CY2023Q4	atai	Convertible Promissory Notes And Derivative Liability Noncurrent ConvertiblePromissoryNotesAndDerivativeLiabilityNoncurrent	2666000
CY2022Q4	atai	Convertible Promissory Notes And Derivative Liability Noncurrent ConvertiblePromissoryNotesAndDerivativeLiabilityNoncurrent	0
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	15047000
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	14702000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	7918000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3664000
CY2023Q4	us-gaap	Liabilities Liabilities	49162000
CY2022Q4	us-gaap	Liabilities Liabilities	39675000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.10
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.10
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.12
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.12
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	166026396
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	166026396
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	166026396
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	166026396
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	165935914
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	165935914
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	165935914
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	165935914
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	18573000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	18562000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	794787000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	774092000
CY2023Q4	atai	Share Subscription Receivable ShareSubscriptionReceivable	0
CY2022Q4	atai	Share Subscription Receivable ShareSubscriptionReceivable	-24000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-19460000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-21702000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-550938000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-510188000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	242962000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	260740000
CY2023Q4	us-gaap	Minority Interest MinorityInterest	1354000
CY2022Q4	us-gaap	Minority Interest MinorityInterest	5026000
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	244316000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	265766000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	293478000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	305441000
CY2023	us-gaap	Revenues Revenues	314000
CY2022	us-gaap	Revenues Revenues	233000
CY2023	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	62203000
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	74313000
CY2023	atai	Acquisition Of In Process Research And Development AcquisitionOfInProcessResearchAndDevelopment	0
CY2022	atai	Acquisition Of In Process Research And Development AcquisitionOfInProcessResearchAndDevelopment	357000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	63582000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	70350000
CY2023	us-gaap	Operating Expenses OperatingExpenses	125785000
CY2022	us-gaap	Operating Expenses OperatingExpenses	145020000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-125471000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-144787000
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	1847000
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	548000
CY2023	us-gaap	Interest Expense InterestExpense	2656000
CY2022	us-gaap	Interest Expense InterestExpense	923000
CY2023	atai	Benefit From Research And Development Tax Credit BenefitFromResearchAndDevelopmentTaxCredit	-2445000
CY2022	atai	Benefit From Research And Development Tax Credit BenefitFromResearchAndDevelopmentTaxCredit	0
CY2023	atai	Change In Fair Value Of Assets And Liabilities Net ChangeInFairValueOfAssetsAndLiabilitiesNet	86583000
CY2022	atai	Change In Fair Value Of Assets And Liabilities Net ChangeInFairValueOfAssetsAndLiabilitiesNet	2083000
CY2023	us-gaap	Impairment Of Investments ImpairmentOfInvestments	1011000
CY2022	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0
CY2023	atai	Gain On Deconsolidation Of A Variable Interest Entity GainOnDeconsolidationOfAVariableInterestEntity	60000
CY2022	atai	Gain On Deconsolidation Of A Variable Interest Entity GainOnDeconsolidationOfAVariableInterestEntity	1484000
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-894000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	6902000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-189000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-489000
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	86185000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9605000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-39286000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-135182000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1016000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6229000
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-3593000
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-16006000
CY2023	us-gaap	Profit Loss ProfitLoss	-43895000
CY2022	us-gaap	Profit Loss ProfitLoss	-157417000
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3671000
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-5032000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-40224000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-152385000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.98
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.98
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	158833785
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	158833785
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	155719585
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	155719585
CY2023	us-gaap	Profit Loss ProfitLoss	-43895000
CY2022	us-gaap	Profit Loss ProfitLoss	-157417000
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2242000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-13366000
CY2023	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-41653000
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-170783000
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	3671000
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	5032000
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	-1000
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	50000
CY2023	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-3672000
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-4982000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-37981000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-165801000
CY2021Q4	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	385959000
CY2022	atai	Issuance Of Subsidiary Preferred Shares IssuanceOfSubsidiaryPreferredShares	600000
CY2022	atai	Issuance Of Subsidiary Common Shares IssuanceOfSubsidiaryCommonShares	357000
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	4913000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2295000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	42375000
CY2022	atai	Foreign Currency Translation Adjustment Net Of Tax ForeignCurrencyTranslationAdjustmentNetOfTax	13316000
CY2022	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-157417000
CY2022Q4	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	265766000
CY2023	atai	Issuance Of Shares Upon Note Conversion IssuanceOfSharesUponNoteConversion	20000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	181000
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	24000
CY2023	atai	Adjustment To Additional Paid In Capital Upon Consolidation Of Variable Interest Entity Net AdjustmentToAdditionalPaidInCapitalUponConsolidationOfVariableInterestEntityNet	-10809000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	-1668000
CY2023	atai	Adjustment To Accumulated Deficit Pursuant To Adoption Of Asu201613 AdjustmentToAccumulatedDeficitPursuantToAdoptionOfAsu201613	-526000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32982000
CY2023	atai	Foreign Currency Translation Adjustment Net Of Tax ForeignCurrencyTranslationAdjustmentNetOfTax	-2241000
CY2023	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-43895000
CY2023Q4	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	244316000
CY2023	us-gaap	Profit Loss ProfitLoss	-43895000
CY2022	us-gaap	Profit Loss ProfitLoss	-157417000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	319000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	168000
CY2023	atai	Noncash Lease Expense NoncashLeaseExpense	383000
CY2022	atai	Noncash Lease Expense NoncashLeaseExpense	0
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	371000
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	131000
CY2023	us-gaap	Research And Development Expense Software Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost	0
CY2022	us-gaap	Research And Development Expense Software Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost	357000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	32982000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	42375000
CY2023	atai	Change In Fair Value Of Assets And Liabilities Net ChangeInFairValueOfAssetsAndLiabilitiesNet	86583000
CY2022	atai	Change In Fair Value Of Assets And Liabilities Net ChangeInFairValueOfAssetsAndLiabilitiesNet	2083000
CY2023	atai	Impairment Of Other Investments ImpairmentOfOtherInvestments	1011000
CY2022	atai	Impairment Of Other Investments ImpairmentOfOtherInvestments	0
CY2023	atai	Gain On Deconsolidation Of A Variable Interest Entity GainOnDeconsolidationOfAVariableInterestEntity	60000
CY2022	atai	Gain On Deconsolidation Of A Variable Interest Entity GainOnDeconsolidationOfAVariableInterestEntity	1484000
CY2023	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	0
CY2022	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	852000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	205000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2294000
CY2023	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	0
CY2022	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	15000000
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	100000
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	1745000
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	5074000
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-799000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	4950000
CY2023	atai	Income Losses From Equity Method Investments IncomeLossesFromEquityMethodInvestments	3593000
CY2022	atai	Income Losses From Equity Method Investments IncomeLossesFromEquityMethodInvestments	16006000
CY2023	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-507000
CY2022	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-161000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-8663000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1522000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2138000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3034000
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3332000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1221000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-84118000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-104467000
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	160262000
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	309058000
CY2023	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	138983000
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	226834000
CY2023	atai	Funds Committed For Investments FundsCommittedForInvestments	25000000
CY2022	atai	Funds Committed For Investments FundsCommittedForInvestments	0
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	259000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	773000
CY2023	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	331000
CY2022	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	251000
CY2023	atai	Cash Paid For Other Investments Held At Fair Value CashPaidForOtherInvestmentsHeldAtFairValue	956000
CY2022	atai	Cash Paid For Other Investments Held At Fair Value CashPaidForOtherInvestmentsHeldAtFairValue	0
CY2023	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	0
CY2022	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	600000
CY2023	us-gaap	Proceeds From Sale Of Other Investments ProceedsFromSaleOfOtherInvestments	486000
CY2022	us-gaap	Proceeds From Sale Of Other Investments ProceedsFromSaleOfOtherInvestments	0
CY2023	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	3500000
CY2022	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	3000000
CY2023	atai	Cash Paid For Convertible Notes Receivable Related Party CashPaidForConvertibleNotesReceivableRelatedParty	2014000
CY2022	atai	Cash Paid For Convertible Notes Receivable Related Party CashPaidForConvertibleNotesReceivableRelatedParty	0
CY2023	atai	Cash Paid Upon Aquisition Of Variable Interest Entity CashPaidUponAquisitionOfVariableInterestEntity	443000
CY2022	atai	Cash Paid Upon Aquisition Of Variable Interest Entity CashPaidUponAquisitionOfVariableInterestEntity	0
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-53295000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-86848000
CY2023	us-gaap	Proceeds From Issuance Of Trust Preferred Securities ProceedsFromIssuanceOfTrustPreferredSecurities	0
CY2022	us-gaap	Proceeds From Issuance Of Trust Preferred Securities ProceedsFromIssuanceOfTrustPreferredSecurities	600000
CY2023	atai	Cash Paid For Acquisition Of Noncontrolling Interest CashPaidForAcquisitionOfNoncontrollingInterest	8480000
CY2022	atai	Cash Paid For Acquisition Of Noncontrolling Interest CashPaidForAcquisitionOfNoncontrollingInterest	0
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	20000
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	4636000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-8355000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20785000
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	189000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-1123000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-145578000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-171653000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	190613000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	362266000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	45034000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	190613000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	1923000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	508000
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	1475000
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	652000
CY2023	atai	Noncash Consideration For Acquisition Of Noncontrolling Interest NoncashConsiderationForAcquisitionOfNoncontrollingInterest	2315000
CY2022	atai	Noncash Consideration For Acquisition Of Noncontrolling Interest NoncashConsiderationForAcquisitionOfNoncontrollingInterest	0
CY2023	atai	Noncash Exchange Of Convertible Promissory Note Modification NoncashExchangeOfConvertiblePromissoryNoteModification	1668000
CY2022	atai	Noncash Exchange Of Convertible Promissory Note Modification NoncashExchangeOfConvertiblePromissoryNoteModification	0
CY2023	atai	Noncash Receipt Of Call Option NoncashReceiptOfCallOption	-5062000
CY2022	atai	Noncash Receipt Of Call Option NoncashReceiptOfCallOption	0
CY2023	atai	Noncash Deferred Credit NoncashDeferredCredit	5062000
CY2022	atai	Noncash Deferred Credit NoncashDeferredCredit	0
CY2023	atai	Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities	1377000
CY2022	atai	Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities	487000
CY2023	atai	Issuance Of Subsidiary Shares In Connection With A Stock Purchase Agreement IssuanceOfSubsidiarySharesInConnectionWithAStockPurchaseAgreement	0
CY2022	atai	Issuance Of Subsidiary Shares In Connection With A Stock Purchase Agreement IssuanceOfSubsidiarySharesInConnectionWithAStockPurchaseAgreement	357000
CY2023	atai	Shares Subscriptions Receivable SharesSubscriptionsReceivable	0
CY2022	atai	Shares Subscriptions Receivable SharesSubscriptionsReceivable	24000
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p id="notes" style="font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">N</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ature of Business</span></p><p style="font-size:10pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ATAI Life Sciences N.V. (“atai”, "Company"), headquartered in Berlin, Germany is the parent company of ATAI Life Sciences AG and, along with its subsidiaries, is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape and is dedicated to efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines to achieve clinically meaningful and sustained behavioral change in mental health patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks and uncertainties common to clinical stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, third-party clinical research organizations and manufacturers, protection of proprietary intellectual property and technology, compliance with government regulations and the ability to secure additional capital to fund operations. Therapeutic candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s therapeutic development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from sales.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has incurred significant losses and negative cash flows from operations since its inception. As of December 31, 2023, the Company had cash and cash equivalents of $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">45.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, short-term securities of $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">109.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and its accumulated deficit was $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">550.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company has historically financed its operations through the sale of equity securities, sale of convertible notes, debt financings, and revenue generated from licensing and collaboration arrangements. The Company has not generated any revenues to date from the sale of its product candidates and does not anticipate generating any revenues from the sale of its product candidates unless and until it successfully completes development and obtains regulatory approval to market its product candidates.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company operates and manages the business as one reporting and one operating segment, which is the business of identifying and advancing mental health innovations. The Company has determined that its chief executive officer is the chief operating decision maker (“CODM”). The CODM reviews consolidated operating results to make decisions about allocating resources or capital to specific compounds or projects in line with overall Company’s strategies and goals. The Company operates in two geographic regions primarily in the United States and Germany.</span></p>
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	45000000
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	109200000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-550900000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-left:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions made in the accompanying consolidated financial statements include, but are not limited to the fair value of securities carried at fair value, the fair value of other investments held at fair value, the fair value of convertible notes receivable, accruals for research and development costs, the fair value of contingent consideration liabilities, in-process research and development assets (“IPRD”), noncontrolling interests recognized in acquisitions, and the valuation of stock-based awards.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.<br/> Changes in estimates are recorded in the period in which they become known.</span></p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-left:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments which potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, short-term investments, and all no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tes receivables. The Company’s cash is mainly held in financial institutions in the United States. Amounts on deposit may at times exceed federally insured limits. The credit risk associated with the Company’s investment in all notes receivables is monitored and assessed periodically. The Company does not believe that it is exposed to any significant credit risk related to these instruments.</span></p>
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2200000
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1000000
CY2023Q3	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	500000
CY2022Q4	us-gaap	Minority Interest MinorityInterest	5026000
CY2023	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	0
CY2023	atai	Net Income Loss Attributable To Noncontrolling Interest Preferred NetIncomeLossAttributableToNoncontrollingInterestPreferred	-3673000
CY2023	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	1000
CY2023Q4	us-gaap	Minority Interest MinorityInterest	1354000
CY2021Q4	us-gaap	Minority Interest MinorityInterest	9051000
CY2022	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	957000
CY2022	atai	Net Income Loss Attributable To Noncontrolling Interest Preferred NetIncomeLossAttributableToNoncontrollingInterestPreferred	-4675000
CY2022	atai	Net Income Loss Attributable To Noncontrolling Interest Common NetIncomeLossAttributableToNoncontrollingInterestCommon	-357000
CY2022	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	50000
CY2022Q4	us-gaap	Minority Interest MinorityInterest	5026000
CY2023Q4	us-gaap	Variable Interest Entity Entity Maximum Loss Exposure Amount VariableInterestEntityEntityMaximumLossExposureAmount	6100000
CY2023Q4	us-gaap	Variable Interest Difference Between Carrying Amount And Maximum Exposure VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure	100000
CY2022Q4	us-gaap	Variable Interest Entity Entity Maximum Loss Exposure Amount VariableInterestEntityEntityMaximumLossExposureAmount	6800000
CY2022Q4	us-gaap	Variable Interest Difference Between Carrying Amount And Maximum Exposure VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure	7200000
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0
CY2023Q4	us-gaap	Variable Interest Difference Between Carrying Amount And Maximum Exposure VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure	200000
CY2023Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	1838000
CY2022Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	6755000
CY2023	atai	Equity Method Investment Shares Transaction Date EquityMethodInvestmentSharesTransactionDate	2026-12-31
CY2023	us-gaap	Subsidiary Or Equity Method Investee Cumulative Proceeds Received On All Transactions SubsidiaryOrEquityMethodInvesteeCumulativeProceedsReceivedOnAllTransactions	9600000
CY2022	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	2400000
CY2023	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	2400000
CY2020Q1	atai	Debt Instrument Face Amount Inclusive Other Payments DebtInstrumentFaceAmountInclusiveOtherPayments	1000000
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Loans And Leases Receivable Net Reported Amount LoansAndLeasesReceivableNetReportedAmount	0
CY2022Q4	us-gaap	Loans And Leases Receivable Net Reported Amount LoansAndLeasesReceivableNetReportedAmount	1100000
CY2023	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	5500000
CY2022	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	300000
CY2023Q4	atai	Fair Value Of Common Stock By Applying Discount For Lack Of Marketability FairValueOfCommonStockByApplyingDiscountForLackOfMarketability	0.05
CY2022Q4	atai	Fair Value Of Common Stock By Applying Discount For Lack Of Marketability FairValueOfCommonStockByApplyingDiscountForLackOfMarketability	0.05
CY2023Q4	us-gaap	Other Investments OtherInvestments	0
CY2022Q4	us-gaap	Other Investments OtherInvestments	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.786
CY2023Q4	atai	Accrued External Research And Development Expenses Current AccruedExternalResearchAndDevelopmentExpensesCurrent	3031000
CY2022Q4	atai	Accrued External Research And Development Expenses Current AccruedExternalResearchAndDevelopmentExpensesCurrent	5550000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1101000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	706000
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	715000
CY2023Q4	atai	Prepaid Research And Development Related Expenses PrepaidResearchAndDevelopmentRelatedExpenses	1822000
CY2022Q4	atai	Prepaid Research And Development Related Expenses PrepaidResearchAndDevelopmentRelatedExpenses	4626000
CY2023Q4	us-gaap	Prepaid Taxes PrepaidTaxes	1752000
CY2022Q4	us-gaap	Prepaid Taxes PrepaidTaxes	5631000
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1410000
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	2034000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	846000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1745000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5830000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14036000
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	4941000
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	5260000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5468000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3566000
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	2224000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15256000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17306000
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	200000
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	100000
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	100000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y2M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.127
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1223000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	226000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	275000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	180000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	990000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44000
CY2023Q4	us-gaap	Operating Leases Future Minimum Payments Receivable Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsReceivableRemainderOfFiscalYear	415000
CY2023Q4	us-gaap	Operating Leases Future Minimum Payments Receivable In Two Years OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears	370000
CY2023Q4	us-gaap	Operating Leases Future Minimum Payments Receivable In Three Years OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears	370000
CY2023Q4	us-gaap	Operating Leases Future Minimum Payments Receivable In Four Years OperatingLeasesFutureMinimumPaymentsReceivableInFourYears	370000
CY2023Q4	us-gaap	Operating Leases Future Minimum Payments Receivable In Five Years OperatingLeasesFutureMinimumPaymentsReceivableInFiveYears	123000
CY2023Q4	us-gaap	Operating Leases Future Minimum Payments Receivable OperatingLeasesFutureMinimumPaymentsReceivable	1648000
CY2023Q4	us-gaap	Receivable With Imputed Interest Discount ReceivableWithImputedInterestDiscount	383000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1265000
CY2020Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	5.56
CY2020Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	77200000
CY2020Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	32200000
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	152200000
CY2021Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4900000
CY2023	atai	Operating Cash Flows From Operating Leases OperatingCashFlowsFromOperatingLeases	440000
CY2022	atai	Operating Cash Flows From Operating Leases OperatingCashFlowsFromOperatingLeases	267000
CY2023	atai	Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities	1377000
CY2022	atai	Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities	487000
CY2023Q4	us-gaap	Debt Instrument Convertible Number Of Equity Instruments DebtInstrumentConvertibleNumberOfEquityInstruments	16
CY2023Q4	us-gaap	Loans Held For Sale Maturity Date LoansHeldForSaleMaturityDate	2026-08-01
CY2023	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	175000000
CY2023Q4	atai	Prime Rate Percent PrimeRatePercent	0.0455
CY2023Q4	atai	Accrued Interest Payable AccruedInterestPayable	0.0855
CY2022Q3	atai	Borrowing Amount Percentage BorrowingAmountPercentage	0.33
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	15000000
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	15000000
CY2023Q4	atai	End Of The Term Charge EndOfTheTermCharge	1042000
CY2022Q4	atai	End Of The Term Charge EndOfTheTermCharge	1042000
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	-204000
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	-274000
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-84000
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-113000
CY2023Q4	atai	Unamortized End Of Term Charge UnamortizedEndOfTermCharge	-707000
CY2022Q4	atai	Unamortized End Of Term Charge UnamortizedEndOfTermCharge	-952000
CY2023Q4	us-gaap	Certain Loans Acquired In Transfer Accounted For As Debt Securities Carrying Amount Net CertainLoansAcquiredInTransferAccountedForAsDebtSecuritiesCarryingAmountNet	15047000
CY2022Q4	us-gaap	Certain Loans Acquired In Transfer Accounted For As Debt Securities Carrying Amount Net CertainLoansAcquiredInTransferAccountedForAsDebtSecuritiesCarryingAmountNet	14702000
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	15047000
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	14702000
CY2020Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	4.69
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	16751951
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	100000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.02
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.17
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	19916000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-55845000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-59201000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-79337000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-39286000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-135182000
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1016000
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1155000
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1016000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1155000
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	5074000
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-0
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	5074000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1016000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6229000
CY2023	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-39286000
CY2022	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-135182000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3018
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3018
CY2023	atai	Income Tax Reconciliation Expected Income Tax Expense Benefit IncomeTaxReconciliationExpectedIncomeTaxExpenseBenefit	-11856000
CY2022	atai	Income Tax Reconciliation Expected Income Tax Expense Benefit IncomeTaxReconciliationExpectedIncomeTaxExpenseBenefit	-40791000
CY2023	atai	Income Tax Reconciliation State Income Taxes Net Of Federal Tax Benefit And Valuation Allowance IncomeTaxReconciliationStateIncomeTaxesNetOfFederalTaxBenefitAndValuationAllowance	-3662000
CY2022	atai	Income Tax Reconciliation State Income Taxes Net Of Federal Tax Benefit And Valuation Allowance IncomeTaxReconciliationStateIncomeTaxesNetOfFederalTaxBenefitAndValuationAllowance	-6509000
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	5188000
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	7276000
CY2023	atai	Effect Of Australian Rd Tax Credit Incentives EffectOfAustralianRDTaxCreditIncentives	-582000
CY2022	atai	Effect Of Australian Rd Tax Credit Incentives EffectOfAustralianRDTaxCreditIncentives	-338000
CY2023	atai	Effect Of Taxes Not Provided On Outside Basis Differences In Consolidated Subsidiaries Regarding Fair Value Adjustments EffectOfTaxesNotProvidedOnOutsideBasisDifferencesInConsolidatedSubsidiariesRegardingFairValueAdjustments	0
CY2022	atai	Effect Of Taxes Not Provided On Outside Basis Differences In Consolidated Subsidiaries Regarding Fair Value Adjustments EffectOfTaxesNotProvidedOnOutsideBasisDifferencesInConsolidatedSubsidiariesRegardingFairValueAdjustments	-109000
CY2023	atai	Effect Of Consolidation And Deconsolidation Of Subsidiaries EffectOfConsolidationAndDeconsolidationOfSubsidiaries	3250000
CY2022	atai	Effect Of Consolidation And Deconsolidation Of Subsidiaries EffectOfConsolidationAndDeconsolidationOfSubsidiaries	-1394000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	975000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	216000
CY2023	atai	Compensation Expenses Not Deductible Under Irc Sections CompensationExpensesNotDeductibleUnderIrcSections	1368000
CY2022	atai	Compensation Expenses Not Deductible Under Irc Sections CompensationExpensesNotDeductibleUnderIrcSections	411000
CY2023	atai	Expenses Not Deductible For Tax Purposes ExpensesNotDeductibleForTaxPurposes	600000
CY2022	atai	Expenses Not Deductible For Tax Purposes ExpensesNotDeductibleForTaxPurposes	-324000
CY2023	atai	Effect Of Statutory Accounting Adjustments EffectOfStatutoryAccountingAdjustments	0
CY2022	atai	Effect Of Statutory Accounting Adjustments EffectOfStatutoryAccountingAdjustments	98000
CY2023	atai	Return To Provision And Deferred Tax Adjustments ReturnToProvisionAndDeferredTaxAdjustments	10188000
CY2022	atai	Return To Provision And Deferred Tax Adjustments ReturnToProvisionAndDeferredTaxAdjustments	758000
CY2023	atai	Uncertain Tax Positions UncertainTaxPositions	96000
CY2022	atai	Uncertain Tax Positions UncertainTaxPositions	0
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-5713000
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	46935000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1016000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6229000
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0259
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0461
CY2023Q4	atai	Deferred Tax Assets Stock Based Compensation DeferredTaxAssetsStockBasedCompensation	35062000
CY2022Q4	atai	Deferred Tax Assets Stock Based Compensation DeferredTaxAssetsStockBasedCompensation	31078000
CY2023Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	19312000
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	11975000
CY2023Q4	atai	Deferred Tax Assets Operating Lease Right Of Use Liability DeferredTaxAssetsOperatingLeaseRightOfUseLiability	13000
CY2022Q4	atai	Deferred Tax Assets Operating Lease Right Of Use Liability DeferredTaxAssetsOperatingLeaseRightOfUseLiability	0
CY2023Q4	atai	Deferred Tax Assets Other Deductible Timing Differences DeferredTaxAssetsOtherDeductibleTimingDifferences	1127000
CY2022Q4	atai	Deferred Tax Assets Other Deductible Timing Differences DeferredTaxAssetsOtherDeductibleTimingDifferences	1864000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	120798000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	101062000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	89968000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	95678000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	30830000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	5384000
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	930000
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	908000
CY2023Q4	atai	Deferred Tax Liabilities Unrealised Foreign Exchange DeferredTaxLiabilitiesUnrealisedForeignExchange	4904000
CY2022Q4	atai	Deferred Tax Liabilities Unrealised Foreign Exchange DeferredTaxLiabilitiesUnrealisedForeignExchange	4472000
CY2023Q4	atai	Deferred Tax Liabilities Outside Basis Differences In Equity And Other Investments DeferredTaxLiabilitiesOutsideBasisDifferencesInEquityAndOtherInvestments	2000
CY2022Q4	atai	Deferred Tax Liabilities Outside Basis Differences In Equity And Other Investments DeferredTaxLiabilitiesOutsideBasisDifferencesInEquityAndOtherInvestments	4000
CY2023Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	24982000
CY2022Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	0
CY2023Q4	atai	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	12000
CY2022Q4	atai	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	0
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	30830000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	5384000
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	90000000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	95700000
CY2023Q4	atai	Unremitted Earnings UnremittedEarnings	0
CY2022Q4	atai	Unremitted Earnings UnremittedEarnings	0
CY2023	atai	Federal Tax Loss Carryforward FederalTaxLossCarryforward	162436000
CY2022	atai	Federal Tax Loss Carryforward FederalTaxLossCarryforward	150991000
CY2023	atai	Overseas Tax Loss Carryforward OverseasTaxLossCarryforward	56691000
CY2022	atai	Overseas Tax Loss Carryforward OverseasTaxLossCarryforward	41908000
CY2023	atai	Tax Loss Carryforward TaxLossCarryforward	219127000
CY2022	atai	Tax Loss Carryforward TaxLossCarryforward	192899000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	369000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	369000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	400000
CY2023	us-gaap	Profit Loss ProfitLoss	-43895000
CY2022	us-gaap	Profit Loss ProfitLoss	-157417000
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3671000
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-5032000
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-40224000
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-40224000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-152385000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-152385000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	158833785
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	158833785
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	155719585
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	155719585
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.98
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.98
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	55119122
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	48004257
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2000000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2800000
CY2023	atai	Related Party Reservation Rate Of Common Shares For Ipo RelatedPartyReservationRateOfCommonSharesForIpo	0.27
CY2023	us-gaap	Labor And Related Expense LaborAndRelatedExpense	500000
CY2022	us-gaap	Labor And Related Expense LaborAndRelatedExpense	500000
CY2023Q1	atai	Percentage Of Restructed Workforce PercentageOfRestructedWorkforce	0.30
CY2023	us-gaap	Restructuring Costs RestructuringCosts	3200000
CY2023Q4	us-gaap	Restructuring Reserve RestructuringReserve	0
CY2023	us-gaap	Variable Interest Entity Ownership Percentage VariableInterestEntityOwnershipPercentage	0.10

Files In Submission

Name	View Source	Status
0000950170-24-038138-index-headers.html	Edgar Link	pending
0000950170-24-038138-index.html	Edgar Link	pending
0000950170-24-038138.txt	Edgar Link	pending
0000950170-24-038138-xbrl.zip	Edgar Link	pending
atai-20231231.htm	Edgar Link	pending
atai-20231231.xsd	Edgar Link	pending
atai-ex21_1.htm	Edgar Link	pending
atai-ex23_1.htm	Edgar Link	pending
atai-ex31_1.htm	Edgar Link	pending
atai-ex31_2.htm	Edgar Link	pending
atai-ex32_1.htm	Edgar Link	pending
atai-ex32_2.htm	Edgar Link	pending
atai-ex4_2.htm	Edgar Link	pending
atai-ex97_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img105967536_0.jpg	Edgar Link	pending
img105967536_1.jpg	Edgar Link	pending
img105967536_2.jpg	Edgar Link	pending
img105967536_3.jpg	Edgar Link	pending
img105967536_4.jpg	Edgar Link	pending
img105967536_5.jpg	Edgar Link	pending
img105967536_6.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
atai-20231231_htm.xml	Edgar Link	completed
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ATAI
ATAI Life Sciences N.V. Stock $atai

2024 Q1 Form 10-K Financial Statement

#000095017024038138 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATAI ATAI Life Sciences N.V. Stock $atai

2024 Q1 Form 10-K Financial Statement

#000095017024038138 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATAI
ATAI Life Sciences N.V. Stock $atai